Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ostrand-Rosenberg

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1988
H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatomaM I Nishimura, I Stroynowski, L Hood, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1993
Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunityS Baskar, N Nabavi, L H Glimcher, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1992
Invariant chain alters the malignant phenotype of MHC class II+ tumor cellsV K Clements, S Baskar, T D Armstrong, et al.
Journal of Immunogenetics|August 1, 1989
Transfection of major histocompatibility complex class I and class II genes causes tumour rejectionS Ostrand-Rosenberg, V K Clements, A Thakur, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|January 1, 1991
Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genesS Ostrand-Rosenberg, C Roby, V K Clements, et al.
Cellular Immunology|May 1, 1986
Teratocarcinoma cell MHC antigen expression is regulated in vitro by a soluble noninterferon factorS Ostrand-Rosenberg, M L Schwartzman, T T Hecht, et al.
Clinical and Experimental Immunology|June 1, 1980
Detection of the circulating antibodies to teratocarcinomadefined antigens in patients with testicular tumoursJ Teodorczyk-Injeyan, M A Jewett, C A Burke, et al.
The Journal of Experimental Medicine|February 1, 1995
Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing miceS Baskar, L Glimcher, N Nabavi, et al.
Cellular Immunology|April 15, 1994
MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous miceS Baskar, V Azarenko, E Garcia Marshall, et al.
Advances in Experimental Medicine and Biology|February 23, 1999
Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccinesS Ostrand-Rosenberg, B A Pulaski, T D Armstrong, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1988
H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatomaM I Nishimura, I Stroynowski, L Hood, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1993
Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunityS Baskar, N Nabavi, L H Glimcher, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1992
Invariant chain alters the malignant phenotype of MHC class II+ tumor cellsV K Clements, S Baskar, T D Armstrong, et al.
Journal of Immunogenetics|August 1, 1989
Transfection of major histocompatibility complex class I and class II genes causes tumour rejectionS Ostrand-Rosenberg, V K Clements, A Thakur, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|January 1, 1991
Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genesS Ostrand-Rosenberg, C Roby, V K Clements, et al.
Cellular Immunology|May 1, 1986
Teratocarcinoma cell MHC antigen expression is regulated in vitro by a soluble noninterferon factorS Ostrand-Rosenberg, M L Schwartzman, T T Hecht, et al.
Clinical and Experimental Immunology|June 1, 1980
Detection of the circulating antibodies to teratocarcinomadefined antigens in patients with testicular tumoursJ Teodorczyk-Injeyan, M A Jewett, C A Burke, et al.
The Journal of Experimental Medicine|February 1, 1995
Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing miceS Baskar, L Glimcher, N Nabavi, et al.
Cellular Immunology|April 15, 1994
MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous miceS Baskar, V Azarenko, E Garcia Marshall, et al.
Advances in Experimental Medicine and Biology|February 23, 1999
Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccinesS Ostrand-Rosenberg, B A Pulaski, T D Armstrong, et al.
Pageof 6